

INFLAMMATORY CONDITIONS

Missed opportunities


Inflammatory conditions are a family of autoimmune diseases **affecting the joints, spine, skin, gastrointestinal system and internal organs**. Currently, only two drugs dominate this therapy class although many other options are available.

Care

Humira® and Enbrel® are the most commonly prescribed therapies for inflammatory conditions.

But the number of additional clinically appropriate options for each condition sets the stage for greater price competition.

Market share of prescribed therapies




Adherence

Patients may try several different therapies before stabilizing

21%-36%

of the time, patients discontinue costly treatment within 90 days to start another high-cost therapy

15+ inflammatory therapies are available but only 2 are widely prescribed



7 inflammatory conditions

Lines show which therapies may be prescribed for each condition or indication


Cost \$

The cost of inflammatory therapies has been increasing steadily and shows no sign of stopping.

#1 costliest specialty class over the past 7 years

\$3K+ Average cost per Rx

Spending on inflammatory drugs is expected to **double by 2018**



Our **Inflammatory Conditions Care Value Program**™ segments therapies by indication to drive price competition among clinically equivalent medications. Patients receive important therapies and specialized care from highly trained specialist pharmacists and nurses. And we're sharing risk with plans by reimbursing them for the prescription costs if a patient discontinues therapy early. **Another powerful solution in the Express Scripts SafeGuardRx® suite | express-scripts.com/corporate**